Yahoo
    NYSE American - Nasdaq Real Time Price USD

    AIM ImmunoTech Inc. (AIM)

    0.1607 +0.0062 (+4.01%)
    At close: 4:00:00 PM EST
    0.1600 -0.0007 (-0.44%)
    After hours: 5:36:13 PM EST
    Loading Chart for AIM
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    View More
    AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays

    AIM ImmunoTech’s Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
    GlobeNewswire 26d ago
    AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential

    AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential
    GlobeNewswire 28d ago
    AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video

    AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
    GlobeNewswire 1mo ago
    AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

    AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
    GlobeNewswire 1mo ago
    AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video

    AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
    GlobeNewswire 1mo ago
    AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference

    AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
    GlobeNewswire 2mo ago
    AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point

    AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point
    GlobeNewswire 2mo ago
    AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program

    AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
    GlobeNewswire 3mo ago
    AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

    AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
    GlobeNewswire 4mo ago
    AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series

    AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
    GlobeNewswire 4mo ago
    AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer

    AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
    GlobeNewswire 4mo ago
    View More

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: